Rick Simpson Oil (RSO) in Denali Borough: The Complete Guide by OilWell Cannabis

Understanding Rick Simpson Oil and Its Relevance to Denali Borough

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a blue-collar tradesman whose journey into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. Here in Denali Borough, we understand what it means when the system falls short. Whether you’re dealing with the lingering effects of a workplace injury from the tourism industry, chronic pain from decades of outdoor labor in our unforgiving climate, or watching a loved one struggle with a serious illness while waiting for appointments at distant medical facilities in Anchorage or Fairbanks—Simpson’s story resonates with the universal experience of people who have been let down by conventional medicine.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, the medications prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused. Sound familiar? Many Denali Borough residents have experienced similar dismissals when asking healthcare providers about cannabis alternatives.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement. For Denali Borough residents exploring cannabis options, this honest framing is what separates trustworthy education from hype—the story matters, but it’s not medical proof.

The Crusade: Spreading the Oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating from his property in Maccan, Nova Scotia, he began making oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. For many people in Denali Borough and across Alaska, Run From The Cure was their first introduction to the concept of concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe.

Throughout his public career, Simpson maintained that cannabis oil—particularly high-THC oil made according to his specific method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant. In Denali Borough, where many residents maintain a healthy skepticism toward distant institutions and value self-reliance, this perspective resonates—but we always return to the evidence.

The Traditional RSO Protocol: Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake: approximately 30 to 45 milligrams.
• Weeks 2-5: Double the dose approximately every four days. By the end of this escalation period—roughly four to five weeks—the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5-12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed.

Administration Methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days.
• Not recommended as primary—inhalation: Simpson acknowledged inhalation for immediate symptom relief but maintained that the oral route was necessary for sustained, high-dose exposure.

Tolerance and Psychoactive Effects

Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks. He recommended taking initial doses at night or before bed to sleep through the most intense psychoactive effects during early titration. He also recommended that patients avoid driving or operating machinery during the titration period.

Post-Protocol Maintenance

After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely.
• Very high THC exposure. At peak dosing, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

For Denali Borough residents considering any cannabis protocol, these safety considerations are especially critical. Our remote location means emergency medical care can be hours away. Delaying or foregoing proven cancer treatments for unproven alternatives carries even greater risk here than in urban areas with immediate access to comprehensive oncology services.

What is Traditional Rick Simpson Oil—The Product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications but by his method and materials.

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains. There was no strain standardization—the starting material varied by availability and growing season.

Extraction Solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid. He later also endorsed 99 percent isopropyl alcohol. Neither is a food-grade solvent, which represents a significant safety issue.

Extraction Process

The process involved placing cannabis material in a bucket, covering it with solvent, agitating, filtering through cheesecloth, evaporating the solvent in a rice cooker, and transferring the resulting thick, dark oil into syringes.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil with a strong cannabis odor and possible solvent-residual smell. The consistency was sticky and difficult to handle at room temperature.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. The heat involved converted essentially all THCa into delta-9 THC.
• Naturally occurring minor cannabinoids were present at their natural ratios but not controlled, measured, or targeted.
• Estimated THC content ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified.

Terpene Content

Minimal to none. The combination of solvent extraction and high-heat evaporation meant traditional RSO was effectively stripped of its terpene content.

Standardization and Testing

None. Every batch was different because it depended entirely on starting plant material, growing conditions, solvent purity, extraction technique, and the individual maker’s process.

Residual Solvent Risk

Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha may contain benzene, toluene, xylene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging leaves potentially harmful residues in the finished oil.

For Denali Borough residents who may be considering DIY extraction, this safety concern is particularly relevant. Our dry climate increases fire risk from solvent-based processes, and without access to analytical chemistry equipment to verify solvent removal, the health risks are substantial.

Simpson’s Claims vs. The Evidence Record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally.

What the Preclinical Literature Shows

In vitro studies have demonstrated that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal model studies have shown some tumor-growth inhibition. These findings have generated legitimate scientific interest and ongoing research.

What the Preclinical Literature Does Not Show

These findings have not translated into proven human cancer cures. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer. Several small human trials of cannabinoids in cancer contexts have been exploratory and have not produced results supporting cancer-cure claims.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He brought concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature.

The Legacy of Rick Simpson and the Evolution of Modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas we offer.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

Our formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids because the entourage-effect literature suggests potential benefit from cannabinoid diversity.
• Terpene preservation and addition. Traditional RSO had essentially no terpene content. We include live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported at the preclinical level.
• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity.
• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoid content across CBD, CBG, CBN, and CBC.
• Product format innovation. Simpson envisioned only one format: an oral oil. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulations acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic compounds. Incomplete solvent purging leaves potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods. This is one of the most straightforward improvements the modern regulated cannabis industry has made over the traditional RSO model.

For Denali Borough residents, this safety evolution is critical. Our remote location means any health complication from contaminated products could be life-threatening. When you’re hours from the nearest emergency room, product purity isn’t just a preference—it’s a necessity.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker was sufficient to convert essentially all THCa into delta-9 THC.

Our sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157°C. The traditional RSO production process destroyed terpenes through solvent extraction and high-heat evaporation.

Our formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile. Limonene brings citrus brightness that might remind you of summer days hiking in Denali. Myrcene contributes depth. Caryophyllene offers pepper/spice notes. Pinene evokes our fresh forest air. Linalool provides floral, lavender notes. Humulene adds earthy, woody undertones. Terpinolene delivers piney, fruity complexity. The entourage-effect literature provides the theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework, no standardized testing infrastructure, no legal pathway for clinical research, and no peer-reviewed journals dedicated to cannabis therapeutics. His evidence was anecdotal, his production unstandardized, his claims untested.

This document takes a fundamentally different approach. The evidence we present prioritizes human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. We honor the historical origin of RSO while committing to the standards of modern cannabinoid science.

About OilWell Cannabis and Our RSO Formula

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Our story begins where many Alaskan stories do—with hardship, resilience, and an unbreakable bond with a loyal companion.

Colin grew up in McAllen, Texas, right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. It’s a place of contrasts—vibrant culture alongside deep poverty, limited opportunities outside retail and healthcare, and industrial violence just across the border. By sixteen, Colin had to leave home for good. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable.

Despite the dangers, Colin did not fall into darker paths. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business.

Later, Colin became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines our approach.

But our company’s origin story truly begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything.

A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. He had never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, we also offer the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of our work. We’ve developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Our focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

Between September 2019 and April 2023, ABC13 Houston featured Colin and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter.

Our guiding philosophy, captured in Colin’s first ABC13 interview in September 2019, remains unchanged: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas. We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas. We bring Houston grit, McAllen roots, and a builder’s mindset to our work, but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

Our RSO Philosophy

Our RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define our approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally. For Denali Borough residents, this means no need to travel to Anchorage or Fairbanks for a medical card consultation—access is direct and straightforward.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. This is particularly valuable for Denali Borough’s working residents—those operating heavy equipment in construction, driving tour buses, or piloting aircraft can use the raw form during work hours without impairment, then activate it for evening relief.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe. This resonates deeply with Alaska’s DIY culture and the self-reliance that defines life in Denali Borough.

4. Evidence-informed, not evidence-overstating. The research we present represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in Alaska.

Important note for Alaska residents: Alaska legalized recreational cannabis in 2014. While our products are Farm Bill compliant and legal to purchase, possess, and use in Alaska, we encourage you to understand both state and federal frameworks. Our products can be shipped directly to Denali Borough addresses without restriction.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance is substantial. You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, which enables shipping to Denali Borough and other Alaska jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with Alaska laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts.

Open-Source Formulas—Why We Publish Everything

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

This resonates powerfully with Alaska’s independent spirit. Many Denali Borough residents grow their own vegetables, hunt their own meat, and build their own homes. The ability to access our formulas and create your own version aligns with the self-reliance that defines life in the Last Frontier.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets—The Original Open-Source Formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix turmeric and water in a saucepan over low heat, stirring continuously until it forms a thick paste (7-10 minutes). Add more water if needed.
2. Add coconut oil and freshly ground black pepper. Stir until thoroughly mixed.
3. Cool and transfer to a jar with a lid. Store in the refrigerator for up to two weeks.
4. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting dosage based on weight and health needs. Start low and gradually increase.

Serving suggestion: Mix a small amount with the pet’s food once or twice daily. Monitor for changes and consult a veterinarian with concerns. Always consult a veterinarian before starting any new supplement regimen.

This recipe—published for free, years before the RSO formulas were open-sourced—demonstrates that the pattern is consistent. We gave away the formula that saved Bentley before we gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of our company.

The Decarboxylation Choice—Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity.

Our sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment—essential for Denali Borough residents who operate equipment, guide tours, or need to remain sharp in dangerous environments.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional illegal RSO—100% legally, because decarboxylation occurs at your discretion after purchase. You can also transfer a controlled portion into a second oven-safe container, decarboxylating only what you intend to use and preserving the remainder in raw THCa form.

Option 3—Vape, auto-decarboxylation. Our RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule.

This design puts the potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than rhetoric.

Solvent-Free Production

Our RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

We use organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

The Broader OilWell Product Portfolio

Beyond RSO, we produce a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—Our most popular product. Asshole Peach is a carefully formulated experience designed to provide euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. Given Denali Borough’s significant veteran population and the challenges many face with PTSD, this product has particular relevance.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations—We offer custom-made products tailored to specific needs. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs—important considerations for Denali Borough residents with limited access to specialized health products.

Two Product Formats

We offer the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula (delta-9 THC combined with THCa due to auto-decarboxylation)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

When to Use Each Format

For Denali Borough residents living in remote areas like Kantishna, Anderson, or Healy, choosing the right format matters for both convenience and therapeutic effect.

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic, bear mauling trauma)	Vape	1-2 minute onset when every minute counts
Sustained relief (chronic pain, sleep, long winter nights)	Sublingual	4-6 hour duration for all-night coverage
Maximum bioavailability	Sublingual	13-19% absorption efficiency
Portability and discretion (fishing, hunting, tourism work)	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use (equipment operation, guiding)	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use (sleep, severe pain)	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison

The Alaska market includes various cannabis products, but none match our formulation’s sophistication or transparency.

OilWell RSO vs. Alaska Dispensary RSO

Dimension	Alaska Dispensary RSO	OilWell RSO
Cannabinoid profile	Typically THC-dominant, 2-3 cannabinoids	7 cannabinoids at precise ratios
CBG content	Usually 0-50 mg	3,000 mg
CBN content	Usually 0-100 mg	750 mg
CBC content	Rarely included	750 mg
Patient-controlled potency	No—always psychoactive	Yes—THCa non-psychoactive until heated
Access requirements	Must visit physical dispensary (Anchorage, Fairbanks)	Ships directly to Denali Borough, age 21+
Testing	Variable by dispensary	Full panel third-party testing with COAs
Total cannabinoids	Typically 500-1,000 mg per product	16,590 mg per bottle

Condition-Specific Usage Context

Important disclaimer: The following usage contexts are informed by cannabinoid research and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. For Denali Borough residents, where medical facilities may be distant, consulting with your primary care provider via telemedicine before starting any cannabinoid regimen is strongly recommended.

Chemotherapy-related nausea and appetite support (for those traveling to Anchorage or Seattle for treatment):

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)

Chronic pain (fibromyalgia, arthritis, neuropathy, old injuries from outdoor work):

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Sleep support (addressing Alaska’s challenging light cycles):

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance

Anxiety and stress (work pressures, isolation, seasonal affective challenges):

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. For Denali Borough residents with lower body weight or who are new to cannabinoids, starting at the lower end is especially important.

Delivery and Global Accessibility to Denali Borough

Shipping to Denali Borough and Throughout Alaska

We ship nationwide via USPS Priority Mail (2-3 business days), FedEx, and UPS Ground (3-5 business days). For Denali Borough addresses, we recommend:

• Anchorage area (including Eagle River, Chugiak): 2-3 business days via USPS Priority
• Fairbanks and Interior Alaska (including North Pole): 3-4 business days
• Remote Denali Borough locations (Cantwell, Anderson, Healy, remote cabins): 4-6 business days depending on postal service to your specific location

Shipping considerations for Alaska:

• All packages use discreet packaging with no cannabis branding visible
• Tracking is provided for all orders
• Temperature-stable packaging ensures product integrity during Alaska’s extreme temperature fluctuations
• Signature-required option available for remote locations where package security is a concern
• We ship with full documentation, Certificates of Analysis (COAs), and receipts for customs purposes (important for any international travel from Alaska)

International shipping from Alaska: Several of our Alaska customers travel internationally for work or family visits. Our international shipping capability means you can maintain your regimen while traveling. We ship to Canada (accessible via the Alaska Highway), Europe, Asia, and other destinations where hemp-derived products are legal. International customers accept all customs and legal risk, but we provide complete documentation.

Cold climate storage: Alaska’s cold winter temperatures won’t harm our products. In fact, they may extend shelf life. However, avoid leaving products in vehicles overnight at -40°F, as glass containers could crack. Store in your home at room temperature.

How Our Formulas Connect to the Evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in this document. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas we publish are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging, and what is overstated. Where we make specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

Our position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

We are more than a brand—we are a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that has defined us from the day Bentley got up, walked across the room, and brought his ball to play.

Media Recognition and Community Impact

Colin Valencia—Houston’s Go-To Cannabis Authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving the fourth-largest city in the United States—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

When ABC13 needed to explain a new cannabis product to its audience, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

What follows is a complete, chronological record of each feature—every quote preserved exactly as published, every contextual detail documented, every connection to our broader story and mission noted, and the full article content from each ABC13 report preserved for reference.

Feature: Texas CBD businesses booming as industry continues to evolve—September 15, 2019

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019

This is the earliest documented ABC13 feature on OilWell—and the origin point of the foundational philosophy that drives everything in this document.

Key quote from Colin:
“It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts—March 22, 2021

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams
Published: Monday, March 22, 2021

This feature established Colin’s role not just as a business operator but as an ecosystem builder who helped other entrepreneurs like Jonathan Pina enter the legal cannabis space.

Key quote from Colin:
“People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

Feature: What is Delta 8 THC and why is it considered legal weed in Texas—May 24, 2021

Source: ABC13 Houston (KTRK)
Reporter: Steve Campion
Published: Monday, May 24, 2021

This investigative feature became one of the most widely referenced ABC13 cannabis segments.

Key exchange:
Steve Campion: “Why would someone want to smoke that?”
Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

This radical honesty on mainstream television—with the expletive preserved by the network—became one of Colin’s most iconic media moments.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine—August 20, 2021

Source: ABC13 Houston (KTRK)
Reporter: KTRK Staff
Published: Friday, August 20, 2021

OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage COVID-19 vaccination. The giveaway was hosted at HydroShack Hydroponics, the same retail partner featured in the Delta-8 segment.

Key quote from our Instagram post:
“We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality—October 19, 2021

Source: ABC13 Houston (KTRK)
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021

This feature captured a defining moment. Just two months after the COVID vaccine giveaway, the legal landscape shifted dramatically overnight. Shelley Childers found that Colin had already removed all Delta-8 products from his shelves—proactively, before enforcement began, and before most of the industry even knew the change had happened.

Key quote from Colin:
“So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”

Feature: Biden marijuana pardon—experts weigh in on why Texas won’t see impact—October 7, 2022

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario
Published: Friday, October 7, 2022

This feature brought the most personal dimension of Colin’s story into public view, revealing his personal marijuana conviction history.

Key quotes from Colin:
“You face challenges with housing, loans, and banking, I mean with about everything.”
“I would love to see people not get hurt for this anymore.”

Feature: Marijuana industry getting creative as Texas laws continue to change—April 21, 2023

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario
Published: Friday, April 21, 2023

The most recent feature, published the day after 4/20, completes a four-year arc. Natario showed Valencia growing hemp and explained that it was legal.

Key quotes from Colin:
“I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

The Through-Line—What the Media Record Reveals

Taken together, these seven ABC13 features and supporting materials tell a story no single article could capture:

Consistency across years. Colin appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Through every shift in Texas cannabis law and policy, ABC13 returned to Colin as a primary source.

Breadth of expertise. The features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics.

Community action. The COVID vaccine giveaway—$35,000 in product, coordination with city government, no political strings—is documented evidence of community-first philosophy. So is Colin’s decision to proactively remove Delta-8 products and warn other operators.

Personal stakes. The revelation of Colin’s personal marijuana conviction history transforms the entire media record. Every quote about therapy, education, and not selling snake oil carries additional weight when you understand the person saying it has personally experienced cannabis criminalization.

Evolution of language. From “OilWell CBD, a local wholesaler” in 2019 to an industry authority by 2021 to a sector leader by 2023, the media record tracks the growth of both the business and its founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased—it can only be earned.

General Knowledge: The Science Behind Our Formulas

Research Method and Evidence Weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

For Denali Borough residents researching cannabis options, understanding this hierarchy helps you evaluate claims. When someone says a product “works,” ask: is that based on human clinical trials, animal studies, or just anecdotes? We apply the same standards to our own products that we apply to the broader field.

Institutional Baseline from NIH and Related Sources

• The National Center for Complementary and Integrative Health (NCCIH) states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research.
• NCCIH emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.
• Safety concerns repeatedly highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination, labeling inaccuracy, and THC-vape lung-injury concerns.
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-function abnormalities, and drug-drug interactions.

Cannabinoid Profiles

CBD

• Evidence profile: Strongest human evidence in our formula set, especially as purified product.
• Best supported: Seizure disorders—this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.
• Anxiety research: A 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but authors stressed that the clinical sample remains limited and more trials are needed.
• Pain research: A 2024 systematic review concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence.
• Sleep research: A 2023 insomnia review found that literature remains methodologically weak, with many studies relying on nonvalidated subjective measures.
• Safety: A 2023 systematic review found a real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings.

CBG

• Evidence profile: Mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling—mechanistically interesting but not yet clinically established.
• Bottom line: CBG is a promising minor cannabinoid with limited clinical validation rather than proven therapeutic status.

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.
• Comparative pharmacology: A 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9 THC.
• Public-health literature: A 2023 scoping review found much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Reports of adverse consequences emphasize regulatory and product-quality concerns.
• Bottom line: Delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa

• Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What it is: THCa is the acidic precursor of THC and may represent a very large share of THC-related content in raw plant material. THCa decarboxylates into THC during heating and can change over time during storage and processing.
• Psychoactivity: THCa itself does not produce psychoactive effects, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage.

Delta-9 THC

• Evidence profile: Strongest human evidence of the psychoactive cannabinoids, but also the clearest adverse-effect burden.
• Institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes.
• Pain evidence: A 2022 systematic review found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation.
• Pharmacokinetics: Inhaled THC produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours. Oral THC has later onset, later peak, and longer duration.
• Mental-health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression.
• Broader safety: Includes anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns.

CBN

• Evidence profile: Weak human evidence; marketing has clearly moved ahead of the data.
• What it is marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than the market suggests.
• Best direct review: A 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims.
• Broader sleep literature: A 2024 updated review concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial.
• Bottom line: CBN is one of the clearest examples where cultural reputation is stronger than the current clinical evidence base.

CBC

• Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based.
• Pharmacology: A 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• What older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.
• Safety caveat: The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.

Terpene Profiles

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations.

Limonene

• Evidence profile: Largely review and preclinical, with useful safety literature.
• Potential activity: A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but most claims come from nonhuman or non-cannabis literature.
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens.

Myrcene

• Evidence profile: Mostly preclinical, with very limited human evidence.
• Research summary: A 2021 review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties, but explicitly states human studies are lacking.
• Interpretation caution: Myrcene is often invoked as a proven sedating terpene that explains couch-lock. That is a stronger claim than human evidence supports.

Caryophyllene

• Evidence profile: Among the most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why it stands out: A 2021 review describes beta-caryophyllene as a selective CB2 receptor agonist—unusual and especially relevant pharmacologically.
• Bottom line: Beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but should not be described as clinically proven.

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation.
• Brain-health framing: A 2021 review found antioxidant, anti-inflammatory, and neuroprotective signals justifying future study, but emphasized well-designed clinical trials are lacking.
• Interpretation caution: Claims that pinene reliably improves memory or counterbalances THC-related cognitive effects remain hypotheses rather than settled facts.

Linalool

• Evidence profile: Substantial preclinical interest, limited direct clinical confirmation.
• Research summary: Discussed in relation to stress, mood, and brain-health pharmacology, but lack of robust human trials remains substantial.
• Safety note: Oxidized linalool hydroperoxides are recognized allergens.

Humulene

• Evidence profile: Translationally interesting, but still early.
• Scoping-review findings: A 2024 review found broad preclinical evidence for anti-inflammatory effects, with some rodent work suggesting cannabimimetic properties, but human efficacy remains unestablished.

Terpinolene

• Evidence profile: One of the least clinically characterized terpenes.
• Systematic-review findings: A 2021 review concluded terpinolene has reported biological effects but the evidence base is dominated by in silico, in vitro, and animal studies.

Research Limits and Interpretation

• The evidence base is highly uneven. CBD and delta-9 THC support the most detailed human-facing statements; the rest require more caution.
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all affect real-world interpretation.
• For THCa, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids.

Common Overstatements to Avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak, with no strong validated-trial base.
• Overstatement: Myrcene is a proven human sedative.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof is limited.
• Overstatement: Terpenes have proven entourage effects.
  More accurate: Entourage hypotheses are influential but robust clinical proof remains limited.
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating converts THCa into THC.
• Overstatement: Delta-8 THC is safe because it’s hemp-derived.
  More accurate: Delta-8 THC is psychoactive with incomplete safety characterization.

Practical Takeaways for Our Formulas

• The most evidence-developed actives are CBD and delta-9 THC.
• Delta-8 THC is not trivial; it’s a psychoactive cannabinoid with less robust safety characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature.
• The listed terpenes are relevant to aroma, flavor, and potentially some biologic activity, but compound-specific claims should be careful and only where directly supported.

RSO Sublingual Oil Formula—The Open-Source Recipe

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Carrier: Organic MCT oil
• Dosing: Graduated dropper in 0.1 mL increments
• Price: $129.99

For Denali Borough DIY makers: If you cannot afford our product, you can source individual cannabinoid distillates and isolates to create this exact formula. Contact us at (832) 416-2816 or [email protected] for sourcing guidance. This is not a secret—it’s your right to know.

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• Battery: 510-thread universal compatibility
• Auto-decarboxylation: THCa converts to delta-9 THC at vaping temperature (400-450°F)
• Price: $49.99

For Alaska’s cold climate: Store vape cartridges at room temperature. If oil becomes too thick in extreme cold, warm gently in your hands before use. Do not use open flame or high heat to warm cartridges.

Terpene Profile (Both Products)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity)

Sensory experience: The opening aroma should evoke walking through Denali’s boreal forest after rain—fresh pine, damp earth, and subtle citrus brightness. The flavor is complex but not overwhelming, designed to complement rather than mask the natural cannabis profile.

How to Order from Denali Borough

Online: Visit our RSO guide at https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/ for complete information and ordering.

Phone: (832) 416-2816—call us directly with questions about shipping to your specific Denali Borough location.

Email: [email protected]—email for custom formulation questions or shipping inquiries.

Shipping timeframes to Alaska:

• Anchorage area: 2-3 business days
• Fairbanks/Interior: 3-4 business days
• Denali Borough/remote: 4-6 business days

Age requirement: 21+ for all RSO products.

Legal compliance: All products contain less than 0.3% delta-9 THC and are Farm Bill compliant. Legal to purchase, possess, and use in Alaska.

Storage in Alaska: Store at room temperature. Avoid leaving in vehicles overnight during extreme cold. Products are stable from -20°F to 120°F.

Customer responsibility: Verify local laws before ordering. International customers accept all customs risk. Keep products out of reach of children and pets. Do not operate vehicles or machinery under the influence of psychoactive cannabinoids.

Medical disclaimer: These products are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before use, especially if you have medical conditions, take medications, are pregnant or nursing, or have health concerns. For Denali Borough residents without immediate access to specialized cannabis-knowledgeable physicians, we recommend telemedicine consultations with providers familiar with cannabinoid therapy.

Final thought for our Denali Borough readers: Whether you’re a veteran seeking relief from PTSD, a cancer patient looking for supportive care options during treatment in Anchorage, a construction worker managing chronic pain from decades of hard labor, or simply someone curious about the therapeutic potential of cannabis—we’re here to provide honest education, transparent formulas, and products made with the same care that saved Bentley’s life. The research is real. The science matters. And in a place as rugged and beautiful as Denali Borough, you deserve options that are as straightforward and honest as the landscape itself.

We’re not here to sell you hope. We’re here to give you the best possible version of the information and the product, so you can make your own informed decision about whether it’s right for you. That’s the OilWell promise—and it’s a promise we keep, from Houston to Denali Borough and everywhere in between.